For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Enoxaparin - VTE treatment in pregnancy
PAD Profile : Enoxaparin - VTE treatment in pregnancy
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Pre-operative / bridging therapy
- VTE prevention post hip/knee replacement
- VTE prophylaxis
- VTE treatment in patients unable to take oral anticoagulants
Additional Documents
Committee Recommendations
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
Note; differences in the mechanisms for operation in needle guard between presentations of enoxaparin.
North West Surrey / ASPH local recommendation:
Ashford & St Peter's Hospitals NHS Foundation Trust are changing the brand of enoxaparin from Clexane to Inhixa (equivalent biosimilar product).
Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.
There are limited indications for which enoxaparin should be prescribed in primary care but, where indicated, North West Surrey in conjunction with ASPH are recommending that practices change to using the Inhixa® brand for all new initiations to support patient safety.
See the "NWS Enoxaparin brand switch" document for details